GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Cyclically Adjusted Price-to-FCF

Eledon Pharmaceuticals (FRA:2TK) Cyclically Adjusted Price-to-FCF : (As of Jun. 15, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eledon Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eledon Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eledon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eledon Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Eledon Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Eledon Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eledon Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eledon Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.268/131.7762*131.7762
=-0.268

Current CPI (Mar. 2024) = 131.7762.

Eledon Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -570.571 100.560 -747.693
201409 -26.481 100.428 -34.747
201412 -37.964 99.070 -50.497
201503 -74.652 99.621 -98.748
201506 -72.000 100.684 -94.234
201509 -66.712 100.392 -87.568
201512 -60.050 99.792 -79.296
201603 -62.586 100.470 -82.087
201606 51.923 101.688 67.286
201609 -9.706 101.861 -12.557
201612 -8.657 101.863 -11.199
201703 -3.986 102.862 -5.106
201706 -549.846 103.349 -701.086
201709 -136.524 104.136 -172.761
201712 -5.585 104.011 -7.076
201803 -76.750 105.290 -96.057
201806 -98.414 106.317 -121.981
201809 -86.724 106.507 -107.300
201812 -101.621 105.998 -126.335
201903 -122.759 107.251 -150.831
201906 -121.000 108.070 -147.543
201909 -3.638 108.329 -4.425
201912 -2.519 108.420 -3.062
202003 -2.073 108.902 -2.508
202006 -2.845 108.767 -3.447
202009 -0.427 109.815 -0.512
202012 -0.511 109.897 -0.613
202103 -0.293 111.754 -0.345
202106 -0.417 114.631 -0.479
202109 -0.407 115.734 -0.463
202112 -0.550 117.630 -0.616
202203 -0.517 121.301 -0.562
202206 -0.412 125.017 -0.434
202209 -0.324 125.227 -0.341
202212 -0.627 125.222 -0.660
202303 -0.649 127.348 -0.672
202306 -0.316 128.729 -0.323
202309 -0.383 129.860 -0.389
202312 -0.279 129.419 -0.284
202403 -0.268 131.776 -0.268

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eledon Pharmaceuticals  (FRA:2TK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eledon Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals (FRA:2TK) Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals (FRA:2TK) Headlines

No Headlines